Who
Cecilia Jones
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Agios Pharmaceuticals; Chief Financial Officer, LogicBio Therapeutics.
In numbers
- Trades disclosed
- 87
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $1.2M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Jan 2021
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,500 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $109K3,141 at $34.71 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,500 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,500 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,500 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $109K3,141 at $34.71 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,666 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,303 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $17K594 at $28.96 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —5,666 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,666 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,000 at $0.00 | filing |
News
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Cecilia Jones; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.